Early warning HPV+ head & neck and anal cancer recurrence, delivered by a simple blood draw.
With cancer, there are often more questions than answers – but here’s what we know about the risk of HPV+ head & neck and anal cancer recurrence:
Detecting recurrence early, when disease burden is low, may improve your chances of long-term survivorship1,2
Symptoms of cancer recurrence can be delayed or subtle
Imaging and clinical exams can miss early signs of head & neck cancer and anal cancer recurrence3,4
Within 5 years of treatment, cancer comes back for up to 1 in 4 HPV+ head & neck cancer patients (recurrence)5,6
Up to one half of first recurrences for head & neck cancer are in a new part of the body (distant metastasis)6
Ask. Test. Know.
The NavDx test is a routine blood test developed to provide a convenient, accurate way to determine whether HPV+ head & neck or anal cancer is present or has come back elsewhere in the body. With the test’s strong predictive value, you can be more confident about whether your HPV+ cancer has returned or not. Ask your doctor about how routine NavDx testing could support your care.
Published studies of people who received treatment for HPV+ cancer show NavDx testing accurately and reliably predicted when cancer returned.7,8,4
For patients with HPV+ head & neck cancer
≥ 95%
of people with one positive test had cancer recur
≥ 98%
of people who routinely tested negative had no cancer recurrence
For patients with HPV+ anal cancer
≥ 96%
of people with one positive test had cancer recur
≥ 92.5%
of people who routinely tested negative had no cancer recurrence
Naveris is Here to Help
Naveris is here to support you. Visit our patient resource center to view more information about mobile phlebotomy, and more resources to guide a discussion with your doctor.
Access Mobile Phlebotomy Service
To connect with our Patient Navigation Team, please email us at support@naveris.com, or call directly at (833) 628-3747 with any questions
Want more details?
Do you have any questions about the NavDx test? We’re here to help. Fill out the form and a Naveris Product Development Representative will contact you.
1. Guo, T.; Kang, S. Y.; Cohen, E. E. W. Front Oncol. 2022, 12, 966899. DOI: 10.3389/fonc.2022.966899.
2. Temperley, H. C.; Mac Curtain, B. M.; O’Sullivan, N. J.; et al. Curr. Oncol. 2024, 31(9), 5151–5163. DOI: 10.3390/curroncol31090381.
3. Chen, A. M.; Harris, J. P.; Gan, M.; et al. JAMA Netw. Open. 2023, 6(11), e2342825. DOI: 10.1001/jamanetworkopen.2023.42825.
4. Kabarriti, R.; Lloyd, S.; Jabalee, J.; Del Vecchio Fitz, C.; Tao, R.; Slater, T.; Jacobs, C.; Inocencio, S.; Rutenberg, M.; Matthiesen, C.; et al. Cancers. 2025, 17, 174. DOI: 10.3390/cancers17020174.
5. Ang, K. K.; Harris, J.; Wheeler, R.; et al. N. Engl. J. Med. 2010, 363(1), 24–35. DOI: 10.1056/NEJMoa0912217.
6. Gillison, M. L.; Trotti, A. M.; Harris, J.; et al. Lancet. 2019, 393, 40–50. DOI: 10.1016/S0140-6736(18)32779-X.
7. Ferrandino, R. N.; Chen, S.; Kappauf, C.; et al. JAMA Otolaryngol Head Neck Surg. 2023. DOI: 10.1001/jamaoto.2023.1937.
8. Hanna, G. J.; Roof, S. A.; Jabalee, J.; et al. Clin. Cancer Res. 2023, 29(20), 4306–4313. DOI: 10.1158/1078-0432.CCR-23-1478.
